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Recent successes with adeno-associated virus (AAV)-based gene therapies fuel the hope
for new treatments for hereditary diseases. Pre-existing as well as therapy-induced
immune responses against both AAV and the encoded transgenes have been described
and may impact on safety and efficacy of gene therapy approaches. Consequently, monitor-
ing of vector- and transgene-specific immunity is mandated and may rationally guide clinical
development. Next to the humoral immune response, the cellular response is central in
our understanding of the host reaction in gene therapy. But in contrast to the monitoring
of antibodies, which has matured over many decades, sensitive and robust monitoring ofT
cells is a relatively new development.To make cellular immune assessments fit for purpose,
investigators need to know, control and report the critical assay variables that influence the
results. In addition, the quality of immune assays needs to be continuously adjusted to
allow for exploratory hypothesis generation in early stages and confirmatory hypothesis
validation in later stages of clinical development.The concept of immune assay harmoniza-
tion which includes use of field-wide benchmarks, harmonization guidelines, and external
quality control can support the context-specific evolution of immune assays. Multi-center
studies pose particular challenges to sample logistics and quality control of sample speci-
mens. Cooperative groups need to define if immune assessments should be performed in
one central facility, in peripheral labs or including a combination of both. Finally, engineered
reference samples that contain a defined number of antigen-specific T cells may become
broadly applicable tools to control assay performance over time or across institutions.
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INTRODUCTION
Inherited diseases account for a substantial number of hospital
admissions of children but also affect adults. Despite progress in
science, efficient treatments that go beyond supportive care are
not available for most of these diseases. Gene replacement thera-
pies bear a high potential to address the medical need in affected
patients and have been introduced to clinical testing about 20 years
ago (1). After many draw-backs in the past an increasing number
of reports of successful gene therapies in patients with hemo-
philia (2), Leber’s congential amaurosis (LCA) (3), or X-linked
adrenoleukodystrophy (4) were recently published. In November
2012, Glybera® (alipogene tiparvovec) was the first human gene
therapy to receive a market approval from the European Medicines
Agency (EMA) suggesting that the field has reached a turning point
which may give raise to additional approved gene therapies in the
future (5).
Most strategies applied for gene replacement focus on two types
of vectors to reach stable transfer of functional gene products into
selected target tissues, namely lentiviral vectors for ex vivo gene
transfer into hematopoietic cells or other stem cells, or adeno-
associated virus (AAV) for in vivo gene transfer to various target
tissues such as muscle, the liver, the retina, lung, or the brain.
Despite successes reported for AAV gene therapy approaches it has
become clear that humoral and cellular immune responses against
both the vector as well as the transgene may negatively impact
on safety and efficacy of gene therapy approaches (6). Humoral
responses against AAV frequently occur in the population, increase
by age and are efficiently induced following a single adminis-
tration of AAV-based therapies. Neutralizing antibodies against
AAV have been shown to negatively influence transduction rates
and may counter-act therapy approaches with systemic delivery
of AAV in particular. More recently, pre-existing antigen-specific
T cells recognizing AAV capsid proteins have been suggested to
be an independent factor leading to reduced transduction rates
on one hand and immune-mediated clearance of transduced
cells expressing capsid proteins on the other hand, which led to
immune-related adverse events in patients (7, 8). The first results
showing that human CD8+ T cells to AAV capsid could limit the
efficacy of the gene transfer originated form an initial trial of AAV
gene transfer to the liver for treatment of hemophilia (7). Here it
could be shown that expression of the initially expressed factor IX
(F.IX) disappeared after several weeks, accompanied by a transient
elevation of transaminases of the liver that were shown to be medi-
ated by antigen-specific T cells directed against AAV but not the
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therapeutic F.IX that eliminated vector-transduced hepatocytes. In
addition, extensive T cell monitoring from multiple studies per-
formed in gene transfer to the muscle indicate that there is a dose
dependent increase in treated patients showing T cell reactivity
against the AVV capsid. Interestingly, currently available data sug-
gest that gene transfer to immune-privileged body compartments
such as the eye and central nervous system so far did not lead to
detectable immune responses to the capsid or the transgene. In
summary, the immunogenicity data found in the clinical studies
conducted with AAV-based vectors in human and available in liter-
ature, confirm that immune responses against AAV capsid proteins
can vary widely and amongst others are influenced by the target
organ, route of delivery, and dosing schedule (9). Also antigen-
specific T cells against the encoded therapeutic gene have been
described and may reduce efficacy of gene therapy (10). All these
findings explain why approaches to better understand or block
immune responses following gene transfer with viral vectors have
recently come into focus in the field (11).
Adeno-associated virus-specific T cells have been shown to be
directed against AAV capsid proteins inducing transient hepati-
tis following i.v administration of AAVs targeting the liver (7).
Although transient toxicity may be acceptable for regenerating
tissues such as the liver in regard of safety, immune-mediated
removal of AAV-transduced cells may become a major obstacle
for gene transfer into toxicity relevant organs such as the brain
or the heart. AAV-specific immunity may also lead to safety con-
cerns as well as efficacy loss in replacement of the retinal pigment
epithelium-specific 65-kDa protein gene in the retina in patients
with LCA as re-therapy in the other eye may be mandated (12).
The currently available data on AAV-therapy induced immu-
nity supports the notion that detailed knowledge of the presence
of antigen-specific T cells prior to gene therapy as well as the
occurrence of vector- and transgene-specific immunity following
therapy may guide clinical decision making in the future (6, 9).
Examples for proactive use of immunological data for the ben-
efit of patients could be: (i) the selection of patients that have a
high likelihood to exert the wanted effects, (ii) identification of
patients that may need an adaption of the therapy (e.g., lower
doses, improved vector), or (iii) receive concomitant immune-
suppression until immunogenic capsid proteins are cleared. It may
also be used to (iv) identify patients at risk for adverse immune
reactions following second administration of the vector, or (v) be
early indicators of loss of function of the encoded gene product.
In order to confirm the hypothesis that data generated by
immunological monitoring can indeed impact on clinical decision
making to enhance AAV-mediated gene therapy, more system-
atic analyses of AAV-specific T cell immunity are mandated and
have even been recommend by NIH Recombinant DNA Advisory
Committee (13). The fact that T cell assays may have a higher com-
plexity and variability as compared to assays to quantify soluble
analytes explains why all investigators that perform correlative bio-
marker studies should know, control and report on the variables
of assay conduct that are known to critically affecting immune
assay performance. The critical variables were identified by large
scale proficiency programs conducted by the Cancer Research
Institute’s Cancer Immunotherapy consortium (CRI-CIC), the
Cancer Immunotherapy Immunoguiding Program (CIMT-CIP)
(14), and the Human Immunophenotyping Consortium (15). In
addition analytical labs are advised to optimize and standardize
sample logistics and assay conduct prior to testing specimens
from clinical trials even at the earliest stage of clinical devel-
opment in which hypothesis generation represents the primary
aim of immune assay use. Assay qualification and validation
become mandatory requirements when a hypothesis generated
in exploratory research from early clinical development has to be
confirmed in advanced clinical development (16). This gradual
evolution of immune assays from first exploratory use toward val-
idated assays performed under Good Clinical Laboratory Practice
(GCLP) standards may be supported by assay harmonization at
any stage (Figure 1).
IMMUNE ASSAY HARMONIZATION AND VARIABLES THAT
IMPACT ON ASSAY PERFORMANCE
A plethora of assays exists to evaluate specific T cell responses,
wanted or unwanted. These assays differ in their sensitivity to
detect low frequency T cells, quantity of information obtainable,
ability to determine structural and/or functional features of T cells,
and their complexity in qualification and validation demands (17).
For years the field of T cell monitoring has been plagued by a
seemingly inherent variability in assay results, even between assays
evaluating the same sample in the same laboratories or by differ-
ent laboratories. A divergence of Standard Operating Procedures
(SOPs), the introduction of new reagents and tools by manu-
facturers, preferences by the assay performing scientist, varying
availability of equipment or the qualification, and training status
of personnel, has further complicated the issue. Due to the lack of
stringent QC procedures as required for clinical diagnostic tests,
many assay “cooks” brewed their own results “soups” following
their recipe without knowledge of how good or how bad that soup
FIGURE 1 | Concept of immune assay harmonization: external quality
assurance, harmonization guidelines, benchmarks for assay
performance, and reference samples with defined numbers of
functional antigen-specificT cells can be used to control the
performance of immune assay in one lab. Immune assay harmonization
can support quality of immune assays at any step of assay development
and use, starting from the initial assay development until assay validation.
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“tasted.” An additionally complicating fact is the limited avail-
ability of test samples, and the intrinsic biological variability in
performance of such samples, a factor well known today that has
caused a shift in considerations concerning sample handling for T
cell monitoring (18–20).
This heterogeneous landscape of assays and protocols exists
in cancer immunology, infectious diseases, transplantation
immunology, and gene therapy. As outlined earlier a multitude
of gene therapy approaches exist that (i) address several unre-
lated diseases, (ii) apply various viral vectors and serotypes, (iii)
target different tissues (e.g., liver, muscle, retina, central nervous
system), (iv) are applied using different administration routes and
(v) deliver various therapeutic gene products. The fact the gene
therapy comes in different flavors mandates a product specific
adaption of the immunological monitoring that acknowledges
therapy-related peculiarities and integrates available knowledge
on immunogenicity and epitope hierarchy of both the applied
vectors and therapeutic transgenes. The fact that there is not one
single assay format that is applicable for all gene therapy trials
poses a challenge on the gene therapy community to agree on
some standards that may be used across a variety of clinical prod-
ucts and studies to generate results that may be comparable across
institutions.
First activities examining the differences in T cell assay per-
formance between laboratories evolved more than 10 years ago
from cancer immunologists and researchers in the HIV field that
initiated proficiency panel projects for ELISPOT (21, 22). This
concept was soon adopted by two non-profit organizations from
the cancer research field, the CIMT-CIP and CRI-CIC, and ele-
vated to highly efficient programs that address proficiency testing
of assay performance of individual labs and the identification of
variables influencing the assay outcome at large (14). By sending
out pretested samples in a blinded fashion to a large number of
laboratories which had to test those sample with a given T cell
assay following their own protocol, and report the results back
to a central site including details about how they performed the
assay, CRI-CIC and CIMT-CIP were able to not only give feedback
on the performance of each individual laboratory in comparison
to the other participating laboratories, but also identified critical
protocol variables that influence the results reported back. These
studies indicated that independent of SOPs applied, the results
of a significant proportion of labs accumulated around an overall
median value in results, while others were outliers. With the help of
protocol information provided, initial recommendations for SOP
adaptations were deduced and introduced to the field for the next
testing round, where it could be confirmed whether these recom-
mendation can indeed improve performance. This iterative testing
process allowed the identification of protocol steps that, indepen-
dent of the SOP applied, could elevate the assay performance
of labs (23–26). These findings are summarized in harmoniza-
tion guidelines which are now increasingly used by laboratories
(Figure 2). The introduction of such harmonization guidelines
has led to significant improvement in response detection across
laboratories (27) and decreased the overall variability in results
between laboratories. Further investigations of specific recom-
mendations have led to even more detailed guidance in the harmo-
nization process, for example by investigating the use of serum-free
freezing and assay media in ELISPOT (28, 29), the implementa-
tion of a dump channel and viability marker in MHC-peptide
multimer staining (26) and obtaining gating recommendations for
flow-based experiments (30, 31). Such assay harmonization activi-
ties, consisting of: (i) a mechanism for regular external proficiency
testing with fast feed-back loops to participants, (ii) dynamic
harmonization guidelines and (iii) benchmarks for assay perfor-
mance, can support investigators to improve and maintain quality
of their assays at any stage of development (Figure 1).
FIGURE 2 | Example of a harmonization guideline: initial guidelines for harmonization of the ELISPOT assay to optimize assay performance and
reproducibility derived from two international proficiency panels, based on their findings and trends observed.
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While this assay harmonization process is ongoing and an
increasing number of labs apply its results, there exists a dis-
crepancy between what is being done in laboratories, and what
is reported when publishing results from T cell assays. To address
the lack of transparency often observed in publications that hin-
ders the accurate interpretation and replication of results, as well
as the comparison of results from different laboratories, the Min-
imal Information about T cell assays (MIATA) project was intro-
duced (32). A 3-year extensive public consensus process involving
more than 100 scientists from the different fields of translational
immunology and regulatory agencies as well as editors from sci-
entific journals resulted in a final reporting framework for results
of T cell assays (33) that summarizes the minimal information to
report about assay conduct. Easy implementation tools are avail-
able online (miataproject.org), and MIATA-compliant papers are
listed with a link to the original publication.
These activities, together with available harmonization guide-
lines, if followed, elevate the T cell immune monitoring field to
a level that allows the creation of high quality data that sup-
port immunotherapeutic developments and advances, and hence
deserve the embracement by the translational science community
at large.
IMMUNE ASSAYS IN MULTI-CENTER CLINICAL TRIALS
A further complicating factor for performing T cell immunomon-
itoring is the complexity and fragility of the analyte. In most cases,
analysis is focused on T cells obtained from peripheral blood; less
often (as more invasive sampling is required) T cells infiltrating
other tissues such as bone marrow or skin are analyzed.
Importantly, functional T cells assays are sensitive to the time
passed since the sample has been taken on a typical scale of hours
(18, 19, 34). In terms of assay validation language, the sample sta-
bility is low. This can be both influenced by the inherent instability
of the T cells and by the instability of the sample matrix such as
granulocytes that become activated over time (35). For some assay
parameters, this time window may be prolonged by adding sta-
bilizers or by isolating the T cells without cryopreservation prior
to shipping the sample (36). More generally, there are two known
solutions to this logistical challenge: (i) all measurements are being
performed within short time using fresh samples, or (ii) all T cells
are isolated from the biological samples and cryopreserved before
the assay.
The first solution may be especially attractive in the case of
monocentric studies. A major drawback of such a scenario is that
no retrospective analyses will be possible, longitudinal samples of
a patient cannot be analyzed within the same assay, and in the
case of multi-centric clinical trials this requires all immune assay
parameters to be fully standardized at each site where patients
are recruited. Therefore, this solution that has been termed as
“peripheral analysis” (37, 38) poses high demands on assay stan-
dardization, which should be completed before a trial is initiated.
Nevertheless, using fresh samples does not control inter-assay
variability, and hence can introduce variability in measurements
of samples obtained from different time points from a patient,
which can confound the response determination between time
points. Determining the precision between measurements of sam-
ples obtained from different time points is logistically challenging,
hence the introduced degree of variability by testing fresh samples
cannot be easily defined.
The second solution requires isolation and cryopreservation of
the T cells shortly after the sample has been taken. Once the cells
are frozen and kept at cryogenic temperatures, they are stable for
very long time periods and can be shipped over great distances to
enable batch-wise analysis within one central lab, thereby reducing
assay variation. This approach does control variability by allowing
the simultaneous testing of samples obtained from different time
points in one assay. However, isolating and cryopreservation of T
cells from biological samples is a relatively laborious process and
is not performed as part of the tests for clinical routine. There-
fore, if it has to be implemented within a multi-centric clinical
trial, all aspects of blood collection, transport to the laboratory
isolating T cells, conduct of the isolation and cryopreservation
process at the lab and shipping of the frozen sample should be
standardized between labs using fully comparable processes and
materials (39). This solution has been termed as “central analy-
sis” (37, 38) and poses high demands on standardized sample
collection, while allowing more flexibility on the assay that are
later being performed with the collected samples. Recent harmo-
nization efforts have addressed cryopreservation challenges, and
provide some guidance (28), while others are still ongoing. The
performance of cell isolation and cryopreservation may be moni-
tored by counting viable cell numbers at the time of isolation and
after thawing the samples and in the case of blood samples the
yield can be additionally monitored by comparing the numbers of
isolated cells to the numbers of lymphocytes and monocytes from
a routine hematology assessment.
To demonstrate the reproducible performance of immunoas-
says over time in one lab during the conduct of a clinical trial,
and between labs as in the case of peripheral analysis, a stable
source of reference samples that can be repeatedly analyzed is of
central importance. For T cell assays, the generation of a stable ref-
erence sample is a challenging task compared to chemical assays,
for example, where a small molecule can be spiked into a sam-
ple matrix at pre-defined concentrations. In the past, labs have
often prepared local reference samples by aliquoting and cryop-
reserving cells from one large blood draw that contained T cells
of a known reactivity. Such reference samples are limited in size,
not comparable between different batches, and do not contain
pre-defined “known” numbers of T cells. Recently, a first gen-
eration of reference samples that contain a defined number of
functional antigen-specific T cells have been developed by CIP
(40). The technology is based on transfer of antigen-specific T
cell receptors (TCRs) into primary lymphocytes using viral gene
transfer. Second generations of reference samples that are based
on the use of in vitro translated RNA for TCR gene transfer are
under development and has been shown to be simple to manu-
facture, robust, and sensitive, stable of at least 1 year and shown
to be suitable for ELISPOT assays, HLA-peptide multimer stain-
ing as well as cytokine flow cytometry applications (unpublished
data). A completed proficiency panel with 12 labs in Europe and
the USA showed that the technology is easily transferable to other
labs and across protocols. Given the currently available data on
T cell reactivity against the AAV capsid, a set of reference sam-
ples engineered with capsid-specific TCRs for the most prevalent
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HLA-restrictions may become a useful tool for the gene therapy
community and help to control assay performance and increase
comparability across different studies using AAV gene transfer.
Thus RNA-based TCR-engineered reference samples may become
a standard tool to control immune assay performance over time
and help destigmatizing T cell assay use in clinical trials an become
yet another component of immune assay harmonization.
CONCLUSION/SUMMARY
Systematic immune assessments in gene therapy trials using qual-
ity controlled immune assays will help to understand the immuno-
logical interactions between AAV-based therapies and the adaptive
immune system. Associating immunological biomarker data with
data on clinical safety and efficacy will enable the field to use
immunomonitoring data for clinical decision making to improve
gene therapy approaches. Prior to use of immune assays investiga-
tors need to know and control those assay variables that determine
the quality of sample specimens and assay results and should
provide structured reporting on the assay setup in publications
and reports. By providing a fast feedback of assay performance
over time or across institutions, assay harmonization can support
immune assay development and use and thus may be considered
as a tool to enhance biomarker research and development of new
immune- and gene-therapies.
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